BRIEF—Amgen launches Amgevita in Europe

US biotech major Amgen says that Amgevita, a biosimilar to adalimumab, will launch in markets across Europe beginning today (October 16).

In March last year, Amgen become the first company to gain European Union approval for a biosimilar version of AbbVie's Humira (adalimumab), the world’s best-selling branded drug.

"The launch of Amgevita in Europe is an important milestone for our biosimilars portfolio, expanding the range of treatment options for the millions of patients living with chronic inflammatory diseases," said Dr David Reese, executive vice president of R&D at Amgen.

“Amgevita is Amgen's second biosimilar to launch in Europe, demonstrating our commitment to providing patients with serious illnesses access to high-quality biological therapies," he added.

Amgen has a total of 10 biosimilars in its portfolio, three of which have been approved by the European Commission.